BusinessMYnd Analytics Announces Uplisting to NASDAQ and Pricing of $8.79M Underwritten OfferingBy Nasdaq OMXJul 14, 2017, 12:30 PM UTC
BusinessMYnd Analytics Declares Special Dividend of Common Stock Warrants to all holders of Common Stock as of July 13, 2017By Nasdaq OMXJul 13, 2017, 11:39 PM UTC
BusinessHarbin Clinic to Launch Personalized Mental Health Program Utilizing MYnd Analytics PEER RegistryBy Nasdaq OMXJul 10, 2017, 11:30 AM UTC
BusinessGenoptix and Bionano Genomics Announce Strategic AllianceBy Nasdaq OMXJun 28, 2017, 12:00 PM UTC
BusinessGeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development PlatformBy Nasdaq OMXMay 30, 2017, 11:03 AM UTC
BusinessGeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development PlatformBy Nasdaq OMXMay 30, 2017, 11:03 AM UTC
BusinessGeneCentric Therapeutics Appoints Walter M. Capone as Chief Business Officer and Adds Ellen Lubman to Board of Directors as Company Advances Drug Development PlatformBy Nasdaq OMXMay 30, 2017, 11:03 AM UTC
